Systemic photoprotection in solar urticaria with α-melanocyte- stimulating hormone analogue [Nle4-D-Phe7]-α-MSH

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 407-414

  Haylett, A K ^a,b   Nie, Z ^a,b   Brownrigg, M ^a,b   Taylor, R ^c   Rhodes, Lesley E ^a,b  

^a Inflammation Sciences Research Group   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE; MELANIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMPLANT; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHOTOREACTIVITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLAR URTICARIA; SPECTRAL SENSITIVITY; TREATMENT RESPONSE; WINTER;

EID: 79551480228     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10104.x     Document Type: Article

References (51)

1. Garbe C, Buttner P, Weisz J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the central malignant melanoma registry of the German Dermatological Society. J Invest Dermatol 1994; 102: 695-9. (Pubitemid 24144245)
2. Schaffer JV, Bolognia JL,. The melanocortin-1 receptor: red hair and beyond. Arch Dermatol 2001; 137: 1477-85.
3. Park H, Kosmadaki M, Yaar M, et al. Cellular mechanisms regulating human melanogenesis. Cell Mol Life Sci 2009; 66: 1493-506.
4. Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007; 128: 853-64.
5. Miller AJ, Tsao H,. New insights into pigmentary pathways and skin cancer. Br J Dermatol 2010; 162: 22-8.
6. Sawyer T, Sanfilippo P, Hruby V, et al. 4-Norleucine, 7-d-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A 1980; 77: 5754-8.
7. Ugwu S, Blanchard J, Dorr R, et al. Skin pigmentation and pharmacokinetics of Melanotan-I in humans. Biopharm Drug Dispos 1997; 18: 259-69.
8. Tatro JB, Reichlin S,. Specific receptors for alpha-melanocyte- stimulating hormone are widely distributed in tissues of rodents. Endocrinology 1987; 121: 1900-7.
9. Vaidyanathan G, Zalutsky MR,. Fluorine-18-labeled [Nle4,-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol 1997; 24: 171-8.
10. Barnetson RS, Ooi TKT, Zhuang L, et al. [Nle4-d-Phe7]-alpha-melanocyte- stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned caucasian volunteers. J Invest Dermatol 2006; 126: 1869-78.
11. Dorr R, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-d-Phe7]-alpha-MSH in humans. Photochem Photobiol 2000; 72: 526-32.
12. Fitzgerald LM, Fryer JL, Dwyer T, et al. Effect of Melanotan®, [Nle4, d-Phe7]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides 2006; 27: 388-94.
13. Dorr RT, Ertl G, Levine N, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol 2004; 140: 827-35.
14. Harms J, Lautenschlager S, Minder C, et al. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 2009; 85: 1434-9.
15. Beattie PE, Dawe RS, Ibbotson SH, et al. Characteristics and prognosis of idiopathic solar urticaria: a cohort of 87 cases. Arch Dermatol 2003; 139: 1149-54.
16. Horio T, Hoelzle E,. Solar urticaria. In: Photodermatology (, Lim H, Hönigsmann H, Hawk J, eds). New York, NY: Informa Healthcare, 2007; 185-197.
17. Hawk J, Eady R, Challoner A, et al. Elevated blood histamine levels and mast cell degranulation in solar urticaria. Br J Clin Pharmacol 1980; 9: 183-6.
18. Soter NA, Wasserman SI, Pathak MA, et al. Solar urticaria: release of mast cell mediators into the circulation after experimental challenge. SID/ESDR Joint Research Meeting, 1979, Amsterdam. J Invest Dermatol 1979; 72: 282 (Abstract).
19. Hernanz A, Muelas G, Borbujo J,. Plasma neuropeptide pattern in acute idiopathic urticaria. Int Arch Allergy Appl Immunol 1989; 90: 198-200.
20. Jong CT, Finlay AY, Pearse AD, et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol 2008; 159: 192-7.
21. Addo H, Sharma S,. UVB phototherapy and photochemotherapy (PUVA) in the treatment of polymorphic light eruption and solar urticaria. Br J Dermatol 1987; 116: 539-47.
22. Bernhard J, Jaenicke K, Momtaz TK, Parrish JA,. Ultraviolet A phototherapy in the prophylaxis of solar urticaria. J Am Acad Dermatol 1984; 10: 29-33.
23. Keahey T, Lavker R, Kaidbey K, et al. Studies on the mechanism of clinical tolerance in solar urticaria. Br J Dermatol 1984; 110: 327-38.
24. Collins P, Ferguson J,. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995; 132: 956-63.
25. Hönigsmann H,. Mechanisms of phototherapy and photochemotherapy for photodermatoses. Dermatol Ther 2003; 16: 23-7.
26. International Association for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 55. Solar and Ultraviolet Radiation. Lyon: International Association for Research on Cancer, 1992.
27. Dwyer T, Muller HK, Blizzard L, et al. The use of spectrophotometry to estimate melanin density in caucasians. Cancer Epidemiol Biomarkers Prev 1998; 7: 203-6.
28. Dwyer T, Blizzard L, Ashbolt R, et al. Cutaneous melanin density of caucasians measured by spectrophotometry and risk of malignant melanoma, basal cell carcinoma, and squamous cell carcinoma of the skin. Am J Epidemiol 2002; 155: 614-21.
29. MacKenzie L, Frain-Bell W,. The construction and development of a grating monochromator and its application to the study of the reaction of the skin to light. Br J Dermatol 1973; 89: 251-64.
30. Wessendorf U, Hanneken S, Haust M, et al. Fixed solar urticaria with delayed onset. J Am Acad Dermatol 2009; 60: 695-7.
31. Ryckaert S, Roelandts R,. Solar urticaria: a report of 25 cases and difficulties in phototesting. Arch Dermatol 1998; 134: 71-4.
32. Kollias N, Sayre R, Zeise L, et al. Photoprotection by melanin. J Photochem Photobiol B 1991; 9: 135-60.
33. Everett M, Yeargers E, Sayre R, et al. Penetration of epidermis by ultraviolet rays. Photochem Photobiol 1966; 5: 533-42.
34. Kaidbey K, Agin P, Sayre R, et al. Photoprotection by melanin-a comparison of black and caucasian skin. J Am Acad Dermatol 1979; 1: 249-60.
35. Brenner M, Hearing V,. The protective role of melanin against UV damage in human skin. Photochem Photobiol 2008; 84: 539-49.
36. Botto NC, Warshaw EM,. Solar urticaria. J Am Acad Dermatol 2008; 59: 909-20.
37. Leenutaphong V, Hölzle E, Plewig G,. Pathogenesis and classification of solar urticaria: a new concept. J Am Acad Dermatol 1989; 21: 237-40.
38. Salamon P, Shoham NG, Gavrieli R, et al. Human mast cells release interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 2005; 60: 1316-19.
39. Shakoory B, Fitzgerald SM, Lee SA, et al. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004; 24: 271-81.
40. Holden N, Gong W, King E, et al. Potentiation of NF-kappaB-dependent transcription and inflammatory mediator release by histamine in human airway epithelial cells. Br J Pharmacol 2007; 152: 891-902.
41. Behrendt H, Lehmann P, Leenutaphong V, et al. Sequential ultrastructural analysis of solar urticaria: inflammatory cells, blood vessels, and nerve fibres. ESDR-JSID-SID Tricontinental Meeting, 1989, Washington DC. J Invest Dermatol 1989; 92: 400 (Abstract).
42. Maurer M, Grabbe J,. Urticaria: its history-based diagnosis and etiologically oriented treatment. Dtsch Arztebl Int 2008; 105: 458-65.
43. Langan EA, Nie Z, Rhodes LE,. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? Br J Dermatol 2010; 163: 451-5.
44. Lipton J, Catania A,. Mechanisms of antiinflammatory action of the neuroimmunomodulatory peptide α-MSH. Ann NY Acad Sci 1998; 840: 373-80.
45. Luger T, Scholzen T, Brzoska T, et al. New insights into the functions of α-MSH and related peptides in the immune system. Ann NY Acad Sci 2003; 994: 133-40.
46. Vulliémoz NR, Xiao E, Xia-Zhang L, et al. Melanocortin modulation of inflammatory cytokine and neuroendocrine responses to endotoxin in the monkey. Endocrinology 2006; 147: 1878-83.
47. Daynes RA, Robertson BA, Cho BH, et al. Alpha-melanocyte-stimulating hormone exhibits target cell selectivity in its capacity to affect interleukin 1-inducible responses in vivo and in vitro. J Immunol 1987; 139: 103-9.
48. Gonindard C, Goigoux C, Hollande E, et al. The administration of an alpha-MSH analogue reduces the serum release of IL-1 alpha and TNF alpha induced by the injection of a sublethal dose of lipopolysaccharides in the BALB/c mouse. Pigment Cell Res 1996; 9: 148-53.
49. Cardones AR, Grichnik JM,. Alpha-melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol 2009; 145: 441-4.
50. Langan EA, Ramlogan D, Jamieson LA, Rhodes LE,. Change in moles linked to use of unlicensed 'sun tan jab'. BMJ 2009; 338: b277.
51. Medicines and Healthcare products Regulatory Agency. Press release: 'Tan-jab' is an Unlicensed Medicine and may not be Safe-Warns Medicines Regulator. 2008. Available at: (last accessed 15 November 2010).